| Document |
Document Title |
|
WO/2024/112902A2 |
|
|
WO/2024/112611A1 |
Provided are compounds that may bind a target protein, and result in modification of the target protein. The compounds may further bind a modifier protein. The modifier protein may carry out or enhance the modification of the target prot...
|
|
WO/2024/112813A2 |
Described herein are polynucleotides for increasing production of rAAV by increasing levels of AAV Capsid proteins, which is achieved by including a strong polyadenylation (polyA) signal sequence 3' to the sequence encoding the AAV capsi...
|
|
WO/2024/081728A3 |
Systems, methods and composition for targeting polynucleotides are detailed herein. In particular, engineered DNA-targeting systems comprising novel TnpB polypeptides and a reprogrammable targeting nucleic acid component and methods and ...
|
|
WO/2024/110069A1 |
The present invention relates to a spinach plant that is resistant to downy mildew caused by Peronospora farinosa. The present invention further relates to a resistance gene that confers resistance to downy mildew in spinach plants and m...
|
|
WO/2024/092112A3 |
Provided herein are methods for identifying antigenic epitopes against the malaria parasite Plasmodium falciparum, Plasmodium malariae, Plasmodium vivax, Plasmodium ovale, and Plasmodium knowlesi in regions endemic for malaria. Also prov...
|
|
WO/2024/086191A3 |
The disclosure relates to immune cells comprising one or more vectors comprising a nucleic acid sequence encoding a chimeric antigen receptor specific for CD 19 and a nucleic acid sequence encoding an enhancer of T cell priming (e.g., IL...
|
|
WO/2024/084398A3 |
The present disclosure relates generally to polynucleotides, vectors, and cells for producing alpha 2 macroglobulin (A2M), methods of making A2M, and compositions comprising A2M. The present disclosure relates generally to polynucleotide...
|
|
WO/2024/112781A1 |
The present invention provides improved P450-BM3 variants with improved activity. In some embodiments, the P450-BM3 variants exhibit improved activity on indanone substrates.
|
|
WO/2024/111974A1 |
The present invention relates to a method for the mass production of immunosuppressive T cells using human serum albumin. According to the present invention, when peripheral blood stem cells (PBSCs) obtained from individuals who have rec...
|
|
WO/2024/111633A1 |
The present invention addresses the problem of providing the induction of antibodies against a target protein using a peptide as an antigen. The present invention relates to a method for preparing a partial peptide that is from within ...
|
|
WO/2024/110509A1 |
The present invention relates to improvements in the production of caseins in non- mammalian host cells, such as yeasts or filamentous fungi. In particular, the invention provides for non-mammalian host cells wherein at least one casein ...
|
|
WO/2024/036328A3 |
Disclosed are recombinant bacteria (e.g., Citrobacter) for producing cationic biological polysaccharide flocculant, and applications of using them. Sequence(s) encoding ribulose carboxylase 1,5-bisphosphate, ribulose phosphorylase, and a...
|
|
WO/2024/112359A1 |
Levels of expression of antibiotic resistance genes are increased up to six-fold by inserting a proteasome-targeting tag into transgenes expressed in eukaryotic cells. Various selectable marker proteins are combined with different destab...
|
|
WO/2024/086738A3 |
Described herein are compositions and methods related to identification of incorporation of non-standard amino acids into proteins using inteins. Also described herein are methods related to development of modified IntN and IntC.
|
|
WO/2024/044684A3 |
The invention relates to proteins and nucleic acids for immunization regimens, modifications thereof, and/or development of nanoparticles, and/or development of membrane-anchored immunogens, and methods of making and using the same. The ...
|
|
WO/2024/110426A1 |
Herein is reported a nucleic acid comprising in operably linked form a nucleic acid encoding a selection marker, a nucleic acid encoding a self-cleaving peptide sequence, and a nucleic acid encoding a proteinaceous protease inhibitor. Fu...
|
|
WO/2024/064784A3 |
Provided herein are methods of treating a mitral valve disease in a subject. The methods involve administering to the subject a gene therapy comprising a first nucleic acid encoding soluble transforming growth factor beta receptor 2 (sTG...
|
|
WO/2023/195805A3 |
The present invention relates to a drug delivery system that specifically binds to integrin beta 2 (ITGB2) on M2 tumor-associated macrophages. The drug delivery system comprising an ITGB2-binding moiety allowing specific binding to ITGB2...
|
|
WO/2024/112133A1 |
The present invention relates to a cassette for expression of a fusion protein from which methionine at the N-terminus has been removed, and use thereof.
|
|
WO/2024/064743A3 |
The disclosure relates to recombinant nucleic acids comprising polynucleotides encoding zinc- finger DNA binding domains (ZF-DBDs), and vectors comprising the same. In some embodiments, the encoded ZF-DBDs are capable of targeting a GATA...
|
|
WO/2024/073664A3 |
This application relates to, in part, modified Botulinum Neurotoxins (BoNTs) comprising modified BoNT/A2 receptor binding domains with increased receptor binding activity, and methods of treatment using the modified BoNT.
|
|
WO/2024/044308A3 |
Provided herein are methods for determining whether a drug impacts ubiquitination of G-coupled protein receptors (GPCRs) and the downstream transducer-mediated signaling of the GPCRs. Also provided are proteins, nucleic acids, vectors, c...
|
|
WO/2024/081592A3 |
Polynucleotides, expression constructs, compositions, kits and method relating to genetic disorders are disclosed. Some embodiments provided herein encompass variants of a protein that relate to a genetic disorder. Also contemplated are ...
|
|
WO/2024/110625A1 |
The present invention relates to compositions for use in methods of preventing or treating retinal diseases or disorders of an animal or a human, wherein said compositions comprise complexes comprising (a) a CRALBP protein, and (b) a cog...
|
|
WO/2024/109479A1 |
The present invention relates to the field of biological medicines, and discloses a polypeptide and a use thereof in the preparation of an anti-fibrosis drug. The amino acid sequence of the polypeptide in the present invention is as show...
|
|
WO/2024/111635A1 |
Provided are: an antibody that recognizes HLA-DR or a functional fragment thereof; a chimeric antigen receptor that supports the antibody or functional fragment thereof; immune cells that express the chimeric antigen receptor; a multispe...
|
|
WO/2024/086827A3 |
According to various aspects of this disclosure, the present disclosure relates a fusion protein comprising i) an antigen-binding portion that binds CD8; and ii) a portion having an IL-2 activity ("IL-2 portion").
|
|
WO/2024/112819A1 |
Disclosed are mutations in the MEN1 gene of cancer cells that affect sensitivity of the cells to menin-inhibitory therapeutics. Also disclosed are diagnostic tests to detect the mutations. Diagnostic testing of cancer cells from a patien...
|
|
WO/2024/040254A3 |
Provided herein are epigenetic-modifying DNA-targeting systems, such as CRISPR-Cas/guide RNA (gRNA) systems, for the transcriptional repression of Hepatitis B viral (HBV) genes to promote a cellular phenotype that leads to the reduction ...
|
|
WO/2024/110191A1 |
The present invention relates to oligonucleotides for induction of elastin de-novo synthesis in mammals, a method of treatment of diseases and medical conditions associated with insufficient tissue elasticity, use of the oligonucleotide ...
|
|
WO/2024/112795A2 |
Provided herein are small-molecule inducible cell suicide switches and their use in cell and gene therapies.
|
|
WO/2024/076500A3 |
In some embodiments, a smart cell drug delivery (SmaCD) system is provided. The SmaCD system can comprise an engineered mammalian regulatory immune cell comprising: (a) a chimeric antigen receptor (CAR) comprising a first binding domain ...
|
|
WO/2024/064748A3 |
The present disclosure provides compositions and methods related to engineered extracellular vesicles (EVs). In particular, the present disclosure provides a novel exosome-specific delivery scaffold for administering therapeutic agents t...
|
|
WO/2024/111982A1 |
The present invention relates to a use of a FGF5 transcript variant 2 (FGF5-v2) gene and a protein thereof for preventing or treating liver fibrosis. The FGF5-v2 fragment gene (transcript and protein expressed therefrom) according to the...
|
|
WO/2024/110932A1 |
of the Disclosure The invention relates to a Fibroblast Growth Factor 2 (FGF-2) polypeptides that have improved stability while maintaining biological activity compared to the wild-type of FGF-2. The invention provides the process for th...
|
|
WO/2024/112809A2 |
Disclosed are peptides and conjugates of the peptide covalently bonded or linked via a linker to a therapeutic or diagnostic molecule, the peptide including at least one cationic domain and at least one hydrophobic domain.
|
|
WO/2024/112814A1 |
The present invention provides novel fusion proteins comprising two cytokines: interleukin-6 (IL-6) and interleukin-1 beta (IL-1β). Methods of using the fusion proteins to activate target cells or treat a disease are also provided.
|
|
WO/2024/109169A1 |
Described in the present application are a series of mature polypeptide sequences. The amino acid sequences of the mature polypeptide sequences are obtained by means of performing modification at at least one of positions 233, 271, 312, ...
|
|
WO/2024/110539A1 |
The present invention discloses the application of Duckweed Pericarp Color1 (P1) protein homologues (P1-Ls) such as LtP1-L or LeP1-L in regulating the biosynthesis of orientin and/or isoorientin in duckweed or other plants. Specifically,...
|
|
WO/2024/110763A1 |
A compound comprising a peptide chain which is an analogue of amylin, a terminal - NH2 group bound to the C terminal of the peptide chain, and an alkylene or alkenylene chain attached at the other end of the peptide chain or a derivative...
|
|
WO/2024/073766A3 |
ASFV is a devastating disease for swine for which there is no treatment or vaccine. The present disclosure provides immunological compositions and methods related to the production and administration of such compositions to reduce the se...
|
|
WO/2024/108312A1 |
The present invention relates to compositions, methods and uses of Teneurin C-Terminal Associated Peptide (TCAP) as an antagonist of corticotropin-releasing factor (CRF). In some other embodiments the invention relates to methods and use...
|
|
WO/2024/092092A3 |
The present application provides compositions, methods, pharmaceuticals, kits comprising recombinant polynucleotides comprising sequence encoding mutant or truncated RFX polypeptides for allogeneic immunotherapies and/or transplantations...
|
|
WO/2024/110675A1 |
The present invention relates to a method of obtaining an exclusively physical concentrated extract of the miraculin protein (MIR). The method is essentially based on membrane ultrafiltration to concentrate the protein without affecting ...
|
|
WO/2024/110878A1 |
Compounds comprising peptides capable of binding C3 protein and inhibiting complement activation are disclosed. The compounds comprise compstatin analogs that can be vectorized for vector-mediated therapy, for example, viral-vector media...
|
|
WO/2024/109611A1 |
Provided is a mutant respiratory syncytial virus pre-fusion F protein, having the following mutations compared with a wild-type respiratory syncytial virus pre-fusion F protein: (a) at least one amino acid residue in an F1 subunit and/or...
|
|
WO/2024/112118A1 |
The present invention relates to stem cells transfected with a vector into which MyoG, MyoD, and Myf6, which are genes for enhancing muscle differentiation, are co-introduced, and a preparation method therefor. When using the present inv...
|
|
WO/2024/086791A3 |
Provided herein at chimeric receptors comprising an IgG Fc receptor and toll/interleukin- 1 receptor (TIR) signaling domain. Further provided are immune effector cells (e.g., NK cells) expressing said chimeric receptors and methods for u...
|
|
WO/2024/086628A3 |
Described herein are compositions and kits comprising recombinant adeno- associated viruses (rAAVs) with increased transduction enrichment in the brain and, in some cases, reduced transduction in the liver. The rAAV compositions describe...
|
